Full Press Release Details
Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting
Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage
immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced
multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting,
being held in a hybrid format (in-person and virtual) from November 9-12 in Boston.
of the presentations are as follows:
The Early Mild Alzheimer's Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595
in Alzheimer's Disease (AD) with inflammation (ADi)
Dr. Judith Jaeger, Cognitionmetrics and Albert Einstein College of Medicine, Stamford, CT and Bronx, NY
Friday, November 12 (onsite)
Analyzing the CSF proteome to support decisions in an AD clinical trial program
Clinical trials: biomarkers including plasma
(on-demand/virtual): LBR7
presentation will be available beginning at 8:00am ET
Novel white matter imaging measures of neuroinflammation, axonal density and demyelination as potential biomarkers for trials in the
AD spectrum: validation in the largescale longitudinal multicenter ADNI studies
Clinical trials: imaging
all posters will be available beginning November 9 at 8:00am ET
MRI measures of white matter pathology can replace CSF sampling in AD clinical trials - case study from the XProTM a
phase 1 trial in Alzheimer's patients with neuroinflammation
Clinical trials: imaging
all posters will be available beginning November 9 at 8:00am ET
Planning for Success: a Three-step process to Define Phase II Trial Size and Duration Using a Patient Enrichment Strategy using Phase
I Data and Public Databases
Clinical trials: methodology
all posters will be available beginning November 9 at 8:00am ET
is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and differentiates itself from existing
TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro could have
substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance
of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication please visit this
section of the INmune Bio's website.
is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple,
essential priming signals akin to treatment with at least three cytokines in combination. INKmune is stable at -80oC and is delivered
by a simple IV infusion. The INKmune:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances
its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide
variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target
the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product
platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic
target of many diseases. DN-TNF is in clinical trial to determine if it can treat for COVID-19 complications (Quellor ), cancer
(INB03 ), Alzheimer's and treatment resistant depression (XPro595), and NASH (LIVNate ). The Natural Killer Cell Priming
Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained
herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain
events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and
uncertainties. INB03 , Quellor , XPro1595, LIVNate , and INKmune are still in clinical trials or preparing to
start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results
will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability
of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies
and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing
and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly
Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this release.
Moss, CFO (858) 964-3720